Monitor for partnering announcements for IMM-529, which is the primary near-term catalyst. The company's cash runway supports operations for ~2 years, reducing near-term dilution risk. Revenue growth is modest but steady; watch for any guidance updates or material agreements.
Price Chart
Executive Summary
Immuron reported FY2026 global sales of A$7.7 million (+6% YoY) and cash of A$10.0 million in its Emerging Growth Conference presentation. The company is pursuing a strategic reset to partner its clinical assets IMM-124E and IMM-529, with Lumanity peak U.S. sales estimates of US$102 million and US$400 million respectively. The filing is a routine investor presentation with no new material events, but the revenue growth and partnering strategy provide a modest positive backdrop.
Key Facts
- FY2026 global sales revenue A$7.7 million, up 6% on prior year
- Australian sales A$5.8 million (+10%), U.S. sales A$1.8 million (+7%, +13% in USD)
- Cash of A$10.0 million at 31 December 2025, up A$7.2 million from June 2025
- Strategic decision to partner IMM-124E and IMM-529 for development and commercialization
- Lumanity peak U.S. sales estimates: IMM-124E US$102 million, IMM-529 US$400 million
- IMM-529 has FDA IND approval for Phase 2; IMM-124E eligible for end-of-Phase 2 FDA meeting
- Cash runway of ~22.5 months based on 1H FY26 operating cash use
Financial Impact
FY2026 revenue of A$7.7M (+6% YoY) and cash of A$10.0M provide stable footing; partnering could unlock significant milestone payments but no deal announced
Risk Factors
- Partnering for IMM-529 may not materialize or could be on unfavorable terms
- Competition in C. difficile infection space (VOWST, REBYOTA) could limit market opportunity
- Canada sales declined 55% YoY, indicating geographic concentration risk
- Reliance on OTC sales of Travelan and ProIBS for cash flow
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-091379 |
| Document: ea0302654-6k_immuron.htm | 0001213900-26-091379 |
| Document: 0001213900-26-091379-index-headers.html | 0001213900-26-091379 |
| Document: 0001213900-26-091379-index.html | 0001213900-26-091379 |
| Document: 0001213900-26-091379.txt | 0001213900-26-091379 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9300 | awaiting T+60 | — | $0.9300 (+0.00%) |
Oct 23, 2026 4d ago | 6-K | $0.9200 | awaiting T+60 | — | $0.9300 (+1.09%) |
Oct 23, 2026 4d ago | 424B5 | $0.9200 | awaiting T+60 | — | $0.9300 (+1.09%) |
Oct 21, 2026 6d ago | 6-K | $0.9490 | awaiting T+60 | — | $0.9300 (−2.00%) |
Oct 16, 2026 11d ago | 6-K | $0.9821 | awaiting T+60 | — | $0.9300 (−5.30%) |
Oct 13, 2026 14d ago | 6-K | $1.04 | awaiting T+60 | — | $0.9300 (−10.58%) |
Sep 24, 2026 4w ago | 20-F | $1.19 | awaiting T+60 | — | $0.9300 (−21.85%) |
Sep 24, 2026 4w ago | 6-K | $1.19 | awaiting T+60 | — | $0.9300 (−21.85%) |
Sep 21, 2026 5w ago | 6-K | $1.26 | awaiting T+60 | — | $0.9300 (−25.90%) |
Sep 4, 2026 7w ago | Press Release | $1.80 | awaiting T+60 | — | $0.9300 (−48.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers